4.7 Article

Dysregulation of Hepatitis B Virus Nucleocapsid Assembly in vitro by RNA-binding Small Ligands

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 434, Issue 10, Pages -

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2022.167557

Keywords

packaging-signal mediated assembly; directly-acting anti-virals; hepatitis B virus

Funding

  1. Medical Research Foundation
  2. UK MRC [MR/N021517/1, MRF-044-0002]
  3. Wellcome Trust [110145, 110146]
  4. Trust of infrastructure and equipment in the Astbury Centre, University of Leeds [089311/Z/09/Z, 090932/Z/09/Z, 106692]
  5. EPSRC [EP/R023204/1]
  6. Royal Society Wolfson Fellowship [RSWF\R1\180009]
  7. Intramural Research Program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services
  8. Astbury Biostructure Facility by the University of Leeds
  9. Engineering and Physical Sciences Research Council [EP/R023204/1] Funding Source: researchfish
  10. Wellcome Trust [089311/Z/09/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

RNA sequences/motifs dispersed across the genome of Hepatitis B Virus regulate formation of nucleocapsid-like particles by core protein in an epsilon/polymerase-independent fashion. Ligands that bind the important RNA Packaging Signals for nucleocapsid assembly were identified, and some of them showed inhibitory effects on the assembly process. While they did not inhibit HBV replication in cell culture, computational modeling suggested the potential of using these ligands as a novel antiviral strategy.
RNA sequences/motifs dispersed across the genome of Hepatitis B Virus regulate formation of nucleocapsid-like particles (NCPs) by core protein (Cp) in vitro, in an epsilon/polymerase-independent fashion. These multiple RNA Packaging Signals (PSs) can each form stem-loops encompassing a Cp-recognition motif, -RGAG-, in their loops. Drug-like molecules that bind the most important of these PS sites for NCP assembly regulation with nanomolar affinities, were identified by screening an immobilized ligand library with a fluorescently-labelled, RNA oligonucleotide encompassing this sequence. Sixty-six of these hits, with affinities ranging from low nanomolar to high micromolar, were purchased as non-immobilized versions. Their affinities for PSs and effects on NCP assembly were determined in vitro by Surface Plasmon Resonance. High-affinity ligand binding is dependent on the presence of an -RGAG-motif within the loop of the PS, consistent with ligand cross-binding between PS sites. Simple structure-activity relationships show that it is also dependent on the presence of specific functional groups in these ligands. Some compounds are potent inhibitors of in vitro NCP assembly at nanomolar concentrations. Despite appropriate logP values, these ligands do not inhibit HBV replication in cell culture. However, modelling confirms the potential of using PS-binding ligands to target NCP assembly as a novel antiviral strategy. This also allows for computational exploration of potential synergic effects between antiviral ligands directed at distinct molecular targets in vivo. HBV PS-regulated assembly can be dysregulated by novel small molecule RNA-binding ligands opening a novel target for developing directly-acting anti-virals against this major pathogen. (C) 2022 The Authors. Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available